To what extent do prescribing practices for hypertension in the private sector in Zimbabwe follow the national treatment guidelines? An analysis of insurance medical claims
Tóm tắt
Hypertension is the most prevalent cardiovascular disease in Zimbabwe. The prevalence of Hypertension in the country is above 30% regardless of the cut off used. Currently, majority of patients in Zimbabwe seek health care from the private sector due to limited government funding for the public health sector. However, Standard treatment guidelines for hypertension are only available in the public sector and are optional in the private sector. This study assesses compliance of private sector prescribing to Standard Treatment guidelines for hypertension. We reviewed hypertension prescription claims to a private health insurance company in Zimbabwe for the period Jan 1-Dec 31 2015. We used the last prescription claimed in the year on the assumption that it represented the patient’s current treatment. Prescription data was analyzed by comparing medicines prescribed to those recommended in the Zimbabwe 7th Essential Medicines List and Standard Treatment Guidelines 2015. We used Microsoft Excel© 2010 to conduct the analysis. A total of 1019 prescriptions were reviewed. Most patients were either on mono or dual therapy (76%). The mostly prescribed class of antihypertensive as first line were Angiotensin Converting Enzyme Inhibitors /Angiotensin Receptor Blockers. Regardless of whether they were being used as first, second or third line this class of antihypertensives emerged as the most prescribed (639 times). Only 358 (35%) prescriptions were compliant with standard treatment guidelines; the rest (661) did not meet several criteria. Areas of non-compliance included use of second line medicines as first line, failure to consider patient characteristics when prescribing, use of contraindicated medicines for certain patients, clinically significant interactions among prescribed medicines and illogical combinations that predispose patients to toxicity. The poor compliance to standard treatment guidelines observed in our study indicates need to improve prescription practices for Hypertension in the private sector in Zimbabwe for its cost-effective management among the covered patients. However, further investigation is needed to understand the drivers of the prescribing habits and the non-compliance to the Essential Medicines List and Standard Treatment guidelines observed. This will enable design of appropriate educational, managerial and economic interventions to improve compliance.
Tài liệu tham khảo
Sawicka K, Syczyrek M, Jatrezbska I, Prasal M, Zwolak A, Daniluk J. Hypertension the silent killer. J Pre-Clin Clin Res. 2011;5(2):43–6.
Zimbabwe National Statistics Agency and the Ministry of Health and Child Care. Zimbabwe national health profile. 2014.
Ministry of Health and Child Care, Zimbabwe. The essential drug list and standard treatment guidelines. 7th ed; 2015.
Ibrahim HM, Damasceno A. Hypertension in developing countries. Lancet. 2012;380:611–9.
Mufunda J, Chatora F, Ndambakuwa Y, Nyarango P, Chifamba J, Kosia A, Sparks VH. Prevalence of non-communicable diseases in Zimbabwe: results from analysis of data from the national central registry and urban survey. Ethn Dis. 2006;16:718–22.
Mutowo MP, Mangwiro JC, Lorgelley P, Owen A, Renzaho A. Hypertension in Zimbabwe: a meta-analysis to quantify its burden and policy implications. World J Metaanal. 2014; 10.13105/wjma.v3.i1.54.
World Health Organization. Non-communicable diseases country profiles. 2014 apps.who.int/iris/bitstream/10665/128038/1/9789241507509_eng.pdf. Accessed on 29 Sept 2016.
World Health Organization. National health survey- Zimbabwe noncommunicable risk factors. 2005.
Ministry of Health and Child Welfare. The national health strategy for Zimbabwe (2009–2013). 2009.
Zimbabwe 2016 Health and Child Care Budget Brief. http://www.unicef.org/Zimbabwe. Accessed on 29 July 2016.
Sacks FM, Compos H. Dietary therapy in hypertension. N Engl J Med. 2010;362:2102–12. Massachusetts Medical Society
Greene R, Harris ND. Pathology and therapeutics for pharmacists; a basis for clinical pharmacy practice. London: The pharmaceutical Press; 1998. p. 75–91.
National Institute of Clinical of Health and Clinical Excellence. Hypertension; the clinical management of hypertension in adults. August 2011.
Evidence based guideline for the management of high blood pressure in Adults. Report from the panel members appointed to the Eight Joint National Committee (JNC8). 2014.
Group Health Cooperative. Hypertension diagnosis and treatment guidelines. August 2014.
American Society of Hypertension and the International Society of hypertension. Clinical Practice guidelines for the management of hypertension in the community: A Statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens. 2014;16(1):14–26.
National Heart Foundation of Australia. Guideline for the diagnosis and management of hypertension in adults-2016. Melbourne: National Heart Foundation of Australia; 2016.
European Society of Hypertension/European Society of Cardiology. Guidelines for the Management of Arterial Hypertension-2013. J Hypertens. 2013;31:1281–357.
Hypertension Canada. CHEP guidelines for blood pressure measurement, diagnosis, assessment of risk, prevention and treatment of hypertension. Can J Cardiol. 2016;32:569–88.
Oral communication with Mr. Josen Sigola, CEO of MASCA.
Association of Healthcare Funders of Zimbabwe. http://www.ahfoz.org. Accessed 29 July 2016.
World Health Organization: Prevention of cardiovascular disease- guidelines for assessment and management of cardiovascular risk. 2007.
Siegel D, Lopez J. Trends in antihypertensive drug use in the United states: do the JNC V recommendations affect prescribing? JAMA. 1997;278:1745–8.
Soumerai SB, Mc Laughlin TJ, Spiegelman D, Hertzmark E, Thibault G, Goldman L. Adverse outcomes of underuse of beta-blockers in elderly survivors of acute myocardial infarction. JAMA. 1997;227:115–21.
Manolio TA, Cutler JA, Furberg CD, Psaty BM, Whelton PK, Applegate WB. Trends in pharmacological management of hypertension in the United States. Arch Intern Med. 1995;155:829–37.
Gross F. Drug utilization-theory and practice the present situation in the Federal Republic of Germany. Eur J Clin Pharmacol. 1981;19:387–92.
Server PS, Messerli FH. Hypertension management 2011: optimal combination therapy. Eur Heart J. 2011;32:2499–506. European Society of Cardiology
Xavier D, Noby M, Pradeep J, Prem P. Letter to the editor. Pattern of drug use in hypertension in a tertiary hospital; a cross sectional study in the inpatients ward. Indian J Pharm. 2001;33:456–7.
Al-Drabah E, Irshaid Y, Yasein N, Zmeili S. Prescription pattern of antihypertensive drugs in family practice clinics at Jordan University Hospital. Med Sci. 2013;2(1):469–88.
Ahmad N, Hassan Y, Tangiisuran B, Meng OL, Abd Aziz N, Khan AH. Guidelines adherence and hypertension control in an outpatient cardiology clinic in Malaysia. Trop J Pharm Res. 2012;11(4):665–72.
Abdulameer SA, Sahib MN, Aziz NA, Hassan Y, Abdul HA, Razzaq A, et al. Physician adherence to hypertension treatment guidelines and drug acquisition costs of antihypertensive drugs at the cardiac clinic: a pilot study. Patient Prefer Adherence. 2012;6:101–8.
Shobana J, Semere M, Sied M, Eyob T, Russom M. Prescribing pattern of anti hypertensive drugs among hypertension patients with cardiac complications in Eritrea. Lat Am J Pharm. 2012;6:101–8.
Jackson JH, Sobolski J, Krienke R, Wong KS, French-Tamas F, Nightengale B. Blood pressure control and pharmacotherapy patterns in the United States before and after release of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure (JNC 7) guidelines. J Am Board Fam Med. 2008;21:512–21.
Ohta Y, Tsuchihashi T, Fujii K, Matsumura K, Ohya Y, Uezono K, et al. Improvement of blood pressure control in a hypertension clinic: a 10 year follow up study. J Hum Hypertens. 2004;18:278.
Jeschke E, Thomas O, Horst CV, Matthias K, Angelina B, Claudia MW, et al. Evaluation of prescribing patterns in a German network of CAM physicians for the treatment of patients with hypertension: a prospective observational study. BMC Fam Pract. 2009;10:78.
Bog-Hansen E, Lindblad U, Ranstam J, Melander A, Rastam L. Antihypertensive drug treatment in a Swedish community: Skaraborg hypertension and diabetes project. Pharmacoepidemiol Drug Saf. 2002;11:45–54.
Ma J, Lee KV, Stafford RS. Changes in antihypertensive prescribing during US outpatient visits for uncomplicated hypertension between 1993 and 2004. Hypertension. 2006;48:846–52.
Campbell NR, Tu K, Brant R, Duong-Hua M, McAlister FA. The impact of the Canadian hypertension education program on antihypertensive prescribing trends. Hypertension. 2006;47:22–8.
Guo JD, Liu GG, Christensen DB, Fu AZ. How well have practices followed guidelines in prescribing antihypertensive drugs: the role of health insurance. Value Health. 2003;6:18–28.
Adam AS, Soumerai SB, Ross-Degnan D. Use of antihypertensive drugs by medicare enrollees: does type of drug coverage matter? Health Aff. 2001;20:276–86.
Ahluwalia JS, McNagny SE, Rask KJ. Correlates of controlled hypertension in indigent, inner-city hypertensive patients. J Gen Intern Med. 1997;12:7–14.
Blustein J. Drug coverage and drug purchases by medicare beneficiaries with hypertension. Health Aff. 2000;19:219–30.
Jackson MG, Drechsler-Martell CR, Jackson EA. Family practice resident’s prescribing patterns. Drug Intell Clin Pharm. 1985;19:205–9.
Mohlala G, Peltzer K, Phaswana-Mafuya N, Ramlagan S. Drug prescription habits in public and private health facilities in 2 provinces in South Africa. East Mediterr Health J. 2010;16(3):324–8.
Holloway KA, Ivanovska V, Wagner AK, Vialle-Valentin C, Ross-Degnan. Have we improved use of medicines in developing and transitional countries and do we know how to? Two decades of evidence. Trop Med Int Health. 18(6):656–64.